新一代抗HIV-1中和抗体的研究进展

2007年德国Merck公司宣布艾滋病病毒（HIV）疫苗失败后，艾滋病疫苗研究陷入低谷。2011年在泰国进行的RV144疫苗显示受试人群获得了31．2％的保护，这个出人意料的结果让研究者重燃信心，即有效的HIV疫苗是可能的。随后，抗HIV-1中和抗体产生条件、靶点、抗体结构及运用等，成为了近年的研究热点。

Research progress of new generation anti-HIV-I neutralizing antibody

Antibodies that neutralize diverse strains of HIV 1 should be broad, potent and with long half- life. Research and development of new HIV-neutralizing monoclonal antibodies （mAbs） have been accelerated by new techniques, particularly the structure biology-guided antigen design with the deep understanding of the epitope structure on the HIV-1 envelope. To study the mechanism of inhibition, the specific features and epitope locations of the new generation mAbs is critical for improving the treatment, protection against HIV-1 infection and developing novel strategies for vaccine design. In this review, we focus on several HIV-neutrali- zing mAbs about their efficacy and potential strategies that will lead to more effective approaches against HIV-1.